Cite

HARVARD Citation

    Kato, Y. et al. (2018). Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions. Cancer science. 109 (10), pp. 3149-3158. [Online]. 
  
Back to record